JP2023523165A - Chk1阻害剤の合成方法 - Google Patents
Chk1阻害剤の合成方法 Download PDFInfo
- Publication number
- JP2023523165A JP2023523165A JP2022561181A JP2022561181A JP2023523165A JP 2023523165 A JP2023523165 A JP 2023523165A JP 2022561181 A JP2022561181 A JP 2022561181A JP 2022561181 A JP2022561181 A JP 2022561181A JP 2023523165 A JP2023523165 A JP 2023523165A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mol
- pharmaceutical composition
- formula
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026032793A JP2026097919A (ja) | 2020-04-07 | 2026-03-02 | Chk1阻害剤の合成方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006305P | 2020-04-07 | 2020-04-07 | |
| US63/006,305 | 2020-04-07 | ||
| PCT/US2021/025977 WO2021207210A1 (en) | 2020-04-07 | 2021-04-06 | Methods for synthesis of chk1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032793A Division JP2026097919A (ja) | 2020-04-07 | 2026-03-02 | Chk1阻害剤の合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523165A true JP2023523165A (ja) | 2023-06-02 |
| JP2023523165A5 JP2023523165A5 (cg-RX-API-DMAC7.html) | 2024-04-16 |
Family
ID=78024095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561181A Pending JP2023523165A (ja) | 2020-04-07 | 2021-04-06 | Chk1阻害剤の合成方法 |
| JP2026032793A Pending JP2026097919A (ja) | 2020-04-07 | 2026-03-02 | Chk1阻害剤の合成方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026032793A Pending JP2026097919A (ja) | 2020-04-07 | 2026-03-02 | Chk1阻害剤の合成方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12606550B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132922A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023523165A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120441567A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020278A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174222A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207210A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
| WO2026108769A1 (en) * | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| JP2009525324A (ja) * | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | インドール誘導体の新規なクエン酸塩およびその医薬用途 |
| JP2015520753A (ja) * | 2012-05-15 | 2015-07-23 | キャンサー・リサーチ・テクノロジー・リミテッド | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| JP4637481B2 (ja) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005034869A2 (en) | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| WO2005037285A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| CN1243033C (zh) | 2004-07-15 | 2006-02-22 | 合肥工业大学 | 一种通过内增韧制备薄膜级聚l-乳酸共聚物的方法 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101189239A (zh) | 2005-04-28 | 2008-05-28 | 休普基因公司 | 蛋白激酶抑制剂 |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| PE20070543A1 (es) | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| EP2134689B1 (en) | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| RU2009147819A (ru) | 2007-05-25 | 2011-06-27 | Астразенека Аб (Se) | Комбинация ингибиторов снк и parp для лечения злокачественных новообразований |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009099601A2 (en) | 2008-02-04 | 2009-08-13 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US8865726B2 (en) * | 2009-09-03 | 2014-10-21 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| US9345705B2 (en) | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2013068755A1 (en) | 2011-11-09 | 2013-05-16 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| CA2860665A1 (en) | 2012-01-05 | 2013-07-11 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| CN102675858A (zh) | 2012-05-22 | 2012-09-19 | 同济大学 | 一种具有形状记忆功能可降解泪管栓塞的制备方法 |
| GB201316526D0 (en) | 2013-09-17 | 2013-10-30 | King S College London | Biomarkers |
| WO2015077602A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating and monitoring cancers |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| SG10201913151TA (en) | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2018102613A2 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
| WO2018191299A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| MX2019012176A (es) | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2018278336A1 (en) | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| JP2021514979A (ja) | 2018-02-26 | 2021-06-17 | シエラ オンコロジー, インコーポレイテッド | Chk1阻害剤を含む癌の治療方法 |
| CA3135165A1 (en) | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| AU2020274164A1 (en) | 2019-05-14 | 2021-11-25 | Sierra Oncology, Inc. | Methods of treating cancer using Chk1 inhibitors |
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
-
2021
- 2021-04-06 CN CN202510460667.8A patent/CN120441567A/zh active Pending
- 2021-04-06 WO PCT/US2021/025977 patent/WO2021207210A1/en not_active Ceased
- 2021-04-06 JP JP2022561181A patent/JP2023523165A/ja active Pending
- 2021-04-06 EP EP21784225.1A patent/EP4132922A4/en active Pending
- 2021-04-06 BR BR112022020278A patent/BR112022020278A2/pt unknown
- 2021-04-06 CA CA3174222A patent/CA3174222A1/en active Pending
- 2021-04-06 US US17/995,564 patent/US12606550B2/en active Active
- 2021-04-06 CN CN202180027747.4A patent/CN115443271A/zh active Pending
-
2026
- 2026-03-02 JP JP2026032793A patent/JP2026097919A/ja active Pending
- 2026-03-20 US US19/573,479 patent/US20260217695A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| JP2009525324A (ja) * | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | インドール誘導体の新規なクエン酸塩およびその医薬用途 |
| JP2015520753A (ja) * | 2012-05-15 | 2015-07-23 | キャンサー・リサーチ・テクノロジー・リミテッド | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
Non-Patent Citations (9)
| Title |
|---|
| ""新医薬品の規格及び試験方法の設定について"", 医薬審発第568号, JPN6010021254, 1 May 2001 (2001-05-01), ISSN: 0005820675 * |
| STEPHEN M. B. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005820679 * |
| 大嶋寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 2007, pages 48 - 53, ISSN: 0005820673 * |
| 小野誠: "塩選択の現状分析", 薬剤学, vol. 73(3), JPN6022047005, 2013, pages 176 - 182, ISSN: 0005820680 * |
| 山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), ISSN: 0005820677 * |
| 川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005820674 * |
| 平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005820672 * |
| 長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), pages 347 - 365, ISSN: 0005820678 * |
| 高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005820676 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230150994A1 (en) | 2023-05-18 |
| EP4132922A1 (en) | 2023-02-15 |
| US12606550B2 (en) | 2026-04-21 |
| CN120441567A (zh) | 2025-08-08 |
| CN115443271A (zh) | 2022-12-06 |
| CA3174222A1 (en) | 2021-10-14 |
| WO2021207210A1 (en) | 2021-10-14 |
| TW202204348A (zh) | 2022-02-01 |
| EP4132922A4 (en) | 2024-07-03 |
| JP2026097919A (ja) | 2026-06-16 |
| US20260217695A1 (en) | 2026-07-30 |
| BR112022020278A2 (pt) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11261161B2 (en) | Processes for preparing ASK1 inhibitors | |
| EP3781563B1 (en) | Hpk1 inhibitors, preparation method and application thereof | |
| KR20240021198A (ko) | Erk 억제제의 제조 방법 | |
| JP7797486B2 (ja) | 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| JP6947749B2 (ja) | チロシンキナーゼ阻害剤及びその誘導体を製造する方法 | |
| JP5575921B2 (ja) | テトラゾールメタンスルホン酸塩の製造方法及びそれに用いられる新規化合物 | |
| WO2019079485A1 (en) | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | |
| JP2016533372A (ja) | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 | |
| KR20180038460A (ko) | 세포독성 벤조다이아제핀 유도체의 제조 방법 | |
| JP2025142218A (ja) | バルベナジンの合成のための方法 | |
| US12606550B2 (en) | Methods for synthesis of CHK1 inhibitors | |
| CN111499640A (zh) | 哌嗪并三唑类衍生物的手性拆分方法 | |
| EP3334735B1 (en) | Processes for preparing an fgfr inhibitor | |
| HK1225388A1 (zh) | 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3,4-二氢-1,4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物 | |
| HK40104000A (en) | Processes for preparing ask1 inhibitors | |
| HK40085073A (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| HK40035686A (en) | Processes for preparing ask1 inhibitors | |
| WO2020140957A1 (en) | Method for preparing sulfonamides drugs | |
| HK1246275B (en) | Processes for preparing ask1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240404 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240404 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250612 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20250612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250901 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260302 |